Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Characteristics and Cardiovascular and Mortality Outcomes in Patients With Type 2 Diabetes Mellitus Initiating Treatment With Sodium-glucose Co-transporter-2 Inhibitors (SGLT-2i) and Other Glucose Lowering Drugs

Trial Profile

Characteristics and Cardiovascular and Mortality Outcomes in Patients With Type 2 Diabetes Mellitus Initiating Treatment With Sodium-glucose Co-transporter-2 Inhibitors (SGLT-2i) and Other Glucose Lowering Drugs

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Dapagliflozin (Primary) ; Canagliflozin; Empagliflozin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms CVD-REAL
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 Oct 2018 Results assessing the outcomes across larger number of countries and patients, presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 20 Sep 2018 According to an AstraZeneca media release, data from this trial will be presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) (Oct 2018).
    • 25 Jun 2018 Results presented in an AstraZeneca media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top